U.S. Markets open in 3 hrs 56 mins


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
6.97-0.08 (-1.13%)
At close: 4:00PM EDT


1 Evertrust Plaza
13th Floor
Jersey City, NJ 07302-6548
United States
201 884 5485

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees27

Key Executives

NameTitlePayExercisedYear Born
Dr. Marco TagliettiCEO, Pres & Director937.35kN/A1960
Mr. Eric FrancoisChief Financial Officer604.91kN/A1975
Mr. David Gonzalez AnguloChief Medical Officer676.13kN/A1965
Mr. Scott Sukenick J.D.Gen. Counsel & Corp. Sec.N/AN/A1978
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase 2 clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.

Corporate Governance

SCYNEXIS, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.